archive-com.com » COM » H » HBMPARTNERS.COM

Total: 38

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • HBM Partners AG - HBM Healthcare Investments
    Healthcare Investments an interesting alternative to investing in big pharma and biotech companies HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange ticker HBMN Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50

    Original URL path: http://www.hbmpartners.com/en/investment-products/hbm-healthcare-investments.php?navid=426340426340 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - HBM Healthcare Investments
    meets your specific requirements and matches your envisaged risks we recommend that you contact an independent financial adviser Furthermore we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances In particular tax treatment depends on individual circumstances and may be subject to change No offer The information contained herein is for informational purposes only and therefore does not constitute an offer or a solicitation of an offer to buy or sell any products or services including but not limited to any shares financial instruments or investment services and it does not engage in any other transaction relating to a specific financial instrument The information cannot be considered as the basis of an investment decision or be considered as a form of solicitation itself Any investment decisions should be based on relevant specific and professional advises In particular you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus the annual and semi annual reports the articles of association as applicable as well as all other documents as required in accordance with local legislation or the regulations applied in your legal jurisdiction or country Performance Past performance is not an indication or guarantee of the future performance of the investment The value of investments may be subject to fluctuations and under certain circumstances investors may not get back the full amount invested The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance Changes in foreign exchange rates may also cause the value of investments to go up or down Applicable Law Place

    Original URL path: http://www.hbmpartners.com/en/investment-products/disclaimer-hbm-overview-public-equity-investment-funds.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - HBM Healthcare Investments
    to access this section of the site and the information contained therein The products are not approved for distribution within Switzerland nor have they specified a representative and paying agent within Switzerland No offer The information contained herein is for information purposes only and therefore does not constitute an offer or a solicitation of an offer to buy or sell any products or services including but not limited to any shares financial instruments or investment services and it does not engage in any other transaction relating to a specific financial instrument The information cannot be considered as the basis of an investment decision or be considered as a form of solicitation itself Any investment decisions should be based on relevant specific and professional advises Accept Decline Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013 29 February 2016 with Morningstar HBM Global Biotechnology Fund

    Original URL path: http://www.hbmpartners.com/en/investment-products/disclaimer-hbm-overview-priavte-equity-investment-funds.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Current Private Portfolio
    PAH and lymphedema Ellipse Technologies USA Adjustable orthopedic implants Company Website www ellipse tech com HBM contact Dr Thomas Thaler Company status private Ellipse Technologies designs develops and commercializes non invasively adjustable remote controlled implants for a broad spectrum of spinal and othopedic applications Ellipse products aid to restore proper anatomic position and aligemnt of the spine and correct limb length discrepancies Gynesonics USA Women s Health Company Website www gynesonics com HBM contact Dr Chandra Leo Company status private Gynesonics focuses on the incision less therapy of symptomatic uterine fibroids the most common benign tumors in women Gynesonics has developed VizAblate a transcervical ultrasound guided ablation system which has a CE Mark in the European Union i Optics Netherlands Diagnostics ophthalmology Company Website www i optics com HBM contact Dr Chandra Leo Company status private he EasyScan scanning laser ophthalmoscope offers a dilation free 3 minute retinal exam for the early detection of diseases such as diabetic retinopathy The Cassini color LED topographer provides a highly precise 3 dimensional map of the cornea supporting e g cataract surgery planning and determination of IOL implants Iconic Therapeutics Drug development ophthalmology Company Website www iconictherapeutics com HBM contact Dr Priyanka Belawat Dr Matthias Fehr Company status private Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines for serious diseases The company s expertise in the role of Tissue Factor TF in angiogenesis inflammation and metastasis has allowed us to develop a unique therapeutic approach to retinal disease and cancer Interventional Spine USA Percutaneous spine implants Company Website www i spineinc com HBM contact Dr Thomas Thaler Company status private Interventional Spine designs develops and markets patented implantable devices for the spine that can be deployed via percutaneous techniques Kolltan Pharmaceuticals USA Drug development oncology Company Website www kolltan com HBM contact Axel Bolte MBA Company status private Kolltan Pharmaceuticals Inc is developing novel monoclonal antibody drugs targeting receptor tyrosine kinases RTKs Lipid Therapeutics Drug development inflammation Company Website lipid therapeutics com HBM contact Dr Alexander Asam Company status private Lipid Therapeutics GmbH is developing novel therapies for inflammatory diseases of the digestive system The company s current focus is to develop LT 02 a delayed release of Phosphatidylcholine for the treatment of Ulcerative colitis LT 02 is currently in PhIII clinical development MiCardia Corporation USA Heart valve implants Company Website www micardia com HBM contact Dr Thomas Thaler Company status private MiCardia is marketing its enCorSQ Mitral Valve Repair System in the Europe The enCorSQ device allows the surgeon to address any recurrent MR or coaptation correction real time off pump on a beating heart days or months after the surgical implant Nabriva Austria Drug development antibacterials Company Website www nabriva com HBM contact Axel Bolte MBA Company status public Nabriva Therapeutics is developing pleuromutilin antibiotics a new class of antibacterial compounds for the treatment of serious infections in humans caused by multi drug resistant pathogens ObsEva Women s Health Company Website www obseva

    Original URL path: http://www.hbmpartners.com/en/portfolio/current-private-portfolio.php?navid=365732365732 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Past Portfolio
    was sold to Roche in 2003 ChemoCentryx USA Drug development inflammation ChemoCentryx was listed on NASDAQ in 2012 China Nuokang China Specialty pharma China Nuokang was listed on NASDAQ in 2009 Corgentech USA Pain therapeutics Corgentech was listed on NASDAQ in 2004 Cytokinetics USA Drug development oncology Cytokinetics was listed on NASDAQ in 2004 Cytos Biotechnology Switzerland Immunotherapy Cytos was listed on SIX Swiss Exchange in 2002 Esbatech Switzerland Next generation anti bodies Esbatech was acquired by Alcon Novartis for 150 million in cash plus contingent payments of up to 439 million Gemin X Canada Drug development oncology Gemin X was acquired by Cephalon for 225 million in 2003 Icagen USA Inflammation Icagen was listed on NASDAQ in 2004 Infinity Pharmaceuticals USA Inflammation Infinity Pharmaceuticals was listed on NASDAQ in 2006 Mediservice Switzerland Drug distribution Mediservice was sold to Galenica in 2007 Micromet Germany USA Antibody drug development Micromet was listed on NASDAQ in 2003 Mpex USA Cystic fibrosis drugs Mpex was acquired by Axcan in 2011 Newron Pharmaceuticals Italy Neurology drugs Newron was listed on SIX Swiss Exchange in 2006 Panomics USA Cellular assays Panomics was acquired by Affymetrix for 73 million in 2008 PharmaSwiss Switzerland Specialty pharma PharmaSwiss was acquired by Valeant for 350 million in 2009 Renovis USA Neurology Renovis was listed on NASDAQ in 2003 Sloning BioTechnology Germany Protein libraries Sloning was sold to Morphosys in 2010 Swedish Orphan Biovitrum SOBI Sweden Oncology drug development Position was sold in 2015 Sunesis Pharmaceuticals USA Drug Development Genetic Diseases Syntonix USA Hemophilia Syntonix was acquired by Biogen Idec for up to 120 million in 2007 Syrrx USA Metabolic diseases Syrrx was acquired by Takeda for 270 million in 2005 Transform Pharmaceuticals USA Drug formulations Transform was acquired by Johnson Johnson for 230 million in 2005 Xenoport USA Neurology

    Original URL path: http://www.hbmpartners.com/en/portfolio/pastportfolio-biopharma.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Past Portfolio
    2011 Northstar Neurosciences USA Stroke rehabilitation Northstar was listed on NASDAQ in 2006 Precimed Switzerland USA Surgical instruments Precimed was sold to GreatBatch for 125 million in 2008 Ziemer Switzerland Eye surgery instruments Sale of position to an investor in 2009 Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease

    Original URL path: http://www.hbmpartners.com/en/portfolio/pastportfolio-medical-technology.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    Technologies MAGEC System 47 KB 1 10 2015 AAA Announces Positive Results From Phase 3 Study NETTER 1 Evaluating Lutathera in Patients with Advanced Midgut Neuroendocrine Tumors 176 KB 27 9 2015 AAA s Lutathera Phase III Meets Primary Endpoint and Data will be Presented in Presidential Session at ECC 2015 115 KB 16 9 2015 Raptor Pharmaceutical Corp Expands Rare Disease Portfolio With the Acquisition of Quinsair TM 19 KB 20 8 2015 Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN 177 for Secondary Hyperoxaluria 200 KB 4 8 2015 Gynesonics raises 43 million in equity financing 326 KB 22 7 2015 AnaptysBio secures 40 million series D financing 85 KB 15 7 2015 Celgene to acquire Receptos advancing leadership in immune inflammatory diseases 33 KB 14 7 2015 MEDIAN Technologies announces a private placement of 19 8 Million at a 12 share price 470 KB 3 7 2015 AAA completes 23 million Euro capital increase with US based institutions 138 KB 23 6 2015 Advanced Accelerator Applications reports over 24 growth in sales for the first quarter of 2015 190 KB 15 6 2015 Eye Diagnostics Innovator i Optics Closes EUR 13 7 Million Financing Round 260 KB 22 5 2015 Curetis to Launch Next Generation Pneumonia Application at ECCMID 2015 191 KB 16 4 2015 New Clinical Data Show Biological Activity of DLX105 in Patients with Behçet s Disease 152 KB 14 4 2015 AAA Reports 29 8 Sales Growth in 2014 and Completes Enrollment in Lutathera Phase III Trial 189 KB 9 4 2015 Nabriva Therapeutics Announces Financing of up to 120M to Advance Clinical Development of New Class of Antibiotic 342 KB 7 4 2015 APR Applied Pharma Research s a APR today announced that HBM BioCapital II a fund advised by HBM Partners Ltd

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2015/news-2015.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    2014 AAA Acquires GE Healthcare s FDG PET Radiopharmaceutical Business in Italy 146 KB 11 09 2014 i Optics and Ophtec collaborate in cataract and refractive surgery market 91 KB 10 9 2014 Kolltan acquires Xetrios Therapeutics 45 KB 9 9 2014 Ophthotech achieves first milestone under Novartis agreement 13 KB 8 9 2014 Delenex Presents Clinical Data on Topical Application of PENTRABodies 96 KB 2 9 2014 CardiacAssist Receives FDA Clearance for PROTEK Cannula 148 KB 28 8 2014 Ellipse Technologies Revolutionary Spinal Deformity Treatment for Children on Display at IMAST this Week 97 KB 17 7 2014 HOYA and i Optics enter into global partnership with novel eye care test for consumers 232 KB 14 7 2014 Pacira Pharmaceuticals Inc Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL 39 KB 26 6 2014 Basilea s oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study 37 KB 2 6 2014 PTC Therapeutics receives positive opinion from CHMP for Translarna ATALUREN 19 KB 23 5 2014 Ophthotech Corporation Announces Closing of Registered Public Offering of Common Stock Including Full Exercise of Underwriters Option to Purchase Additional Shares 45 KB 19 5 2014 Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All Oral Interferon Free Hepatitis C Regimen Containing ABT 450 341 KB 8 5 2014 Pacira Pharmaceuticals Inc Announces sNDA Submission for EXPAREL Nerve Block Indication 40 KB 7 5 2014 Curetis Launches Unyvero i60 Implant and Tissue Infection Cartridge in Europe 4056 KB 7 5 2014 New Favorable Clinical Evaluation Data for Unyvero P50 Pneumonia Application 2318 KB 23 4 2014 Enanta Pharmaceuticals Announces New Drug Application Submission to the U S FDA for All Oral Interferon Free Hepatitis C Regimen

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2014/news-2014.php (2016-04-25)
    Open archived version from archive



  •